Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Comparison of Idarubicin Versus Doxorubicin in Conventional Trans-Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
FY 2023-24
Summary
Title: Comparison of Idarubicin vs Doxorubicin in Conventional Trans-Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
Summary:
Liver cancer, particularly hepatocellular carcinoma (HCC), ranks sixth globally in cancer-related deaths. Trans-arterial chemoembolization (TACE) has become the standard for unresectable HCC, but the choice of chemotherapeutic agents lacks consensus. While Doxorubicin is commonly used, evidence supporting its superiority is scarce. Idarubicin, known for its high cytotoxicity, presents a promising alternative. However, limited human studies make direct comparisons challenging. This retrospective study aims to assess the efficacy of Idarubicin vs Doxorubicin in TACE for unresectable HCC. Objectives include evaluating response rates, time to progression, overall survival, and progression-free survival. The hypothesis posits significant differences between the two agents. The study, conducted at a center transitioning from Doxorubicin to Idarubicin, will analyze electronic medical records spanning 2012 to 2021. Each Idarubicin patient (at least 100) will be matched with two Doxorubicin controls. Data, including baseline characteristics, laboratory values, procedural parameters, and imaging data, will be extracted. Statistical analyses will employ the Kaplan-Meier method, Cox proportional hazard regression model, and t-test for paired samples. The study's significance lies in its potential to guide chemotherapeutic agent selection in TACE, addressing the current lack of standardization. By providing evidence-based insights, this study could contribute to establishing standardized TACE protocols, ultimately improving HCC treatment outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506211
Name
Tran Victor
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparison of Idarubicin Versus Doxorubicin in Conventional Trans-Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Doxorubicin; Idarubicin; Interventional Radiology; Liver Cancer; Minimally Invasive; Radiology; Trans-Arterial Chemoembolization
Abstract
Title: Comparison of Idarubicin vs Doxorubicin in Conventional Trans-Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma
Summary:
Liver cancer, particularly hepatocellular carcinoma (HCC), ranks sixth globally in cancer-related deaths. Trans-arterial chemoembolization (TACE) has become the standard for unresectable HCC, but the choice of chemotherapeutic agents lacks consensus. While Doxorubicin is commonly used, evidence supporting its superiority is scarce. Idarubicin, known for its high cytotoxicity, presents a promising alternative. However, limited human studies make direct comparisons challenging. This retrospective study aims to assess the efficacy of Idarubicin vs Doxorubicin in TACE for unresectable HCC. Objectives include evaluating response rates, time to progression, overall survival, and progression-free survival. The hypothesis posits significant differences between the two agents. The study, conducted at a center transitioning from Doxorubicin to Idarubicin, will analyze electronic medical records spanning 2012 to 2021. Each Idarubicin patient (at least 100) will be matched with two Doxorubicin controls. Data, including baseline characteristics, laboratory values, procedural parameters, and imaging data, will be extracted. Statistical analyses will employ the Kaplan-Meier method, Cox proportional hazard regression model, and t-test for paired samples. The study's significance lies in its potential to guide chemotherapeutic agent selection in TACE, addressing the current lack of standardization. By providing evidence-based insights, this study could contribute to establishing standardized TACE protocols, ultimately improving HCC treatment outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tran, Victor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~